Lucera, a new company emerging from the German biotech firm Molecular Health, aims to enhance data-driven decision-making in drug development by leveraging a knowledge platform developed over 15 years. With a focus on biological explanations for predictions, Lucera addresses the challenge of decision robustness amidst vast data availability in the industry. It will serve over 20 clients globally and is led by former Molecular Health executives. This transition marks a strategic shift as Lucera seeks to grow independently after Molecular Health struggled with its business model, betting on the value of its core data and technology in a competitive AI-driven market.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://european-biotechnology.com/latest-news/a-fresh-start-for-molecular-health-technology-core-becomes-start-up-lucera/
